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Background: Quality of life (QoL) has become a major outcome in the treatment of
patients with cancer. This study is aimed at examining the impact of chemotherapy-induced
nausea and vomiting on QoL of patients with gynecologic cancer in Indonesia.
Methods: Chemotherapy-naive patients with gynecologic cancer, who were treated with
cisplatin at a dosage 50 mg/m2 or higher as monotherapy or as part of combination che-
motherapy regimens, were recruited in the Oncology Department, Dr. Sardjito Hospital,
Yogyakarta, Indonesia. Quality of life was assessed by using the Indonesian version of the
European Organization for Research and Treatment for Cancer of Quality of Life Ques-
tionnaire and Short Form-36, administered immediately before and on day 5 after che-
motherapy administration. Patients used a daily diary to record nausea and vomiting during
5 days after chemotherapy.
Results: Most (74.9%) of the 179 patients experienced delayed emesis during the 5 days
after chemotherapy despite prophylactic use of antiemetics. The delayed nausea and emesis
caused significant negative impact on patients’ QoL. Nausea in the delayed phase caused
negative effects on patients’ QoL.
Conclusions: Patients reported a negative impact on the QoL of delayed emesis after che-
motherapy. Poor prophylaxis of patients’ nausea and vomiting after chemotherapy interferes
with patients’ QoL. Medical and behavioral interventions may help to alleviate the negative
consequences of chemotherapeutic treatment in patientswith gynecologic cancers treatedwith
suboptimal antiemetics.
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In recent decades, quality of life (QoL) has increasingly be-come an important outcome in the treatment of patients
with cancer. In QoL research, the impact of the illness itself
and the cancer treatments are assessed from the patients’ per-
spective. One of the factors most seriously impacting pa-
tients’ QoL during cancer treatment is chemotherapy-induced
nausea and vomiting (CINV), especially when it is inade-
quately treated by antiemetic drugs.1 Patients may experience
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acute or delayed CINV during cancer treatment. Acute CINV
is defined as nausea and vomiting episodes, which persist
during the first 24 hours after chemotherapy administration.2
Delayed CINV starts after the first 24 hours after chemother-
apeutic treatment and may persist up to 120 hours.3 Patients
who experience both acute and delayed CINV have worse
QoL compared with patients with delayed CINVonly or with-
out acute and delayed CINV.1 By using an appropriate pro-
phylactic antiemetic regimen, the incidence of CINV can be
substantially reduced. However, despite the availability of
highly effective antiemetic drugs, approximately 20% to 30%
of the patients treated with highly emetogenic regimens still
experience nausea and vomiting. This is caused by the pres-
ence of some risk factors, such as sex, age, and individual
susceptibility.4 Health professionals often underestimate the
incidence and prevalence of CINV.5
Most gynecologic cancer types are treated with highly
emetogenic chemotherapeutics, such as cisplatin, carboplatin,
paclitaxel, and cyclophosphamide when paclitaxel is not
available.6 These drugs are reported to cause emesis in more
than 90% of patients without prophylactic use of antiemet-
ics7 and may seriously impact QoL. In addition to CINV, the
psychological distress after cancer diagnosis, especially is-
sues concerning femininity, body image, sexuality, and repro-
duction also have been demonstrated to result in a decrease
of the patients’ QoL.5,8
The incidence of cervical cancer in Indonesia is 13.7
per 100,000 women in Indonesia.9 Despite this high inci-
dence, information about the patients’ QoL is still very lim-
ited. Therefore, we undertook this study to assess the QoL
in gynecologic cancer patients after treatment with highly
emetogenic chemotherapeutics, using the European Organi-
zation for Research and Treatment for Cancer of Quality of
Life Questionnaire (EORTC QLQ-C30) as a disease-specific
instrument and the Short Form-36 questionnaire (SF-36) as
a generic instrument for QOL or functional status. Patients’
QoL baseline condition was also determined to know the
change of patients’ QoL after treatment with chemotherapeu-
tics. In addition, we addressed the impact of delayed CINV
on these patients’ QoL.
METHODS
Patients
The study sample consisted of chemotherapy-naive pa-
tients with cervical cancer (n = 120), ovarian cancer (n = 51),
uterine cancer (n = 8), and vulva cancer (n = 7) in the
Oncology Department of Dr. Sardjito Hospital, Yogyakarta,
Indonesia. They were treated with cisplatin at a dosage of
50 mg/m2 or higher as monotherapy or in combination che-
motherapy regimens. Patients with all diagnoses of gyneco-
logic cancer and limited to pelvic or advanced stage of cancer
were allowed to be included. Patients were referred by the
general practitioners to the Dr. Sardjito Hospital, Yogyakarta,
after the diagnosis was made. The staging procedures con-
sisted of physical examination by a gynecologist and limited
imaging when appropriate. Patients in the surgery consid-
eration were treated according to the medical standard in
Indonesia.
According to the standard of prophylactic antiemetic
drug in the hospital, all patients were treated in the out-
patient clinic by 8 mg of intravenous ondansetron and 8 mg
of intravenous dexamethasone 1 hour before cisplatin admin-
istration as a prophylactic antiemetic regimen. All patients
were also given oral metoclopramide 10 mg, 3 times a day,
from day 2 to day 5, to prevent delayed emesis.
Patients aged 18 years or older with a Karnofsky index
of 50% or higher were included. Patients with nausea or
vomiting 24 hours before chemotherapy, use of other anti-
emetics than ondansetron and dexamethasone, use of benzo-
diazepines or neuroleptics, treatment with radiotherapy within
24 hours before the start of chemotherapy, and the use of
opioids within the previous 2 weeks were excluded.
Patients’ sociodemographic data were determined from
their medical records. All patients gave informed consent. Data
collection on demographics and baseline conditions was com-
pleted before administration of the chemotherapeutic drugs.
Patients filled in the EORTC QLQ-C30 and SF-36 question-
naires 1 to 4 hours before chemotherapy and on day 5 after
chemotherapy administration at the hospital. Not all of the
patients could fill in the questionnaires by themselves and
needed researcher assistance to explain some questions, that
is, the questions about general health and general QoL in
EORTC QLQ-C30. Patients were also asked to fill in a daily
diary record to score the degree of nausea and the vomiting
frequency during the 4 days after chemotherapy. The study
was approved by the local ethics committee of the Medical
Faculty, Gadjah Mada University, Yogyakarta.
Measurements
EORTC QLQ-C30 Questionnaire
We used the EORTC QLQ-C30 questionnaire, which is
available in a validated Indonesian translation.10 This original
questionnaire was developed by the EORTC for patients with
all cancer types . The EORTC QLQ-C30 covers basic impor-
tant personal dimensions in cancer patients, in the physical,
psychological, and social domains. Furthermore, this question-
naire also covers cancer symptoms or cancer treatmentYrelated
symptoms such as nausea, vomiting, dyspnea, appetite loss,
diarrhea, constipation, insomnia, as well as financial impact.
The questionnaire has been used extensively in many coun-
tries to assess QoL of cancer in patients in their respective
countries.11 The normative data of Dutch population in fe-
male subjects were used as reference group (n = 796).12
We used the Dutch population as the normative data in this
study because the normative data of EORTC QLQ-C30 in
Indonesian population are not available. The characteristics
of Dutch subjects who filled in the EORTC QLQ-C30 ques-
tionnaire were female respondents (n = 796) and a mean
(SD) age of 50.8 (15) years. Around 63% subjects reported
the health problems as follows: heart disease, hypertension,
asthma/chronic obstructive pulmonary disease, diabetes, de-
pression, and joint disease.
SF-36 Questionnaire
The SF-36 is a generic instrument that can therefore
be used in the general population and any group of patients
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with any illness as a generic QoL instrument.13 The SF-36
has QoL dimensions similar to the EORTC QLQ-C30, that is,
physical, emotional/mental, social, pain, and vitality/energy.
In previous studies that compared the SF-36 and EORTC
QLQ-C30 in patients with cancer, they were found to be sat-
isfactory psychometric instruments in assessing consequences
of cancer on the physical, emotional, social, pain, and energy
dimensions of the questionnaire.14 The normative data from
the Dutch population aged 45 to 54 years old were used as
reference data in this study (n = 180).15 We used the Dutch
population as the reference because of the collaboration study
between the institutions in Indonesia and Netherlands and
the normative data of SF-36 in Indonesia population are not
available.
Delayed Emesis
Delayed emesis was defined as delayed nausea and
vomiting as had to be reported by the patients in their diaries.
Delayed nausea was measured by the Nausea Visual Analog
Scale using a severity nausea scale of 0 to 100.16 Zero on
the scale represents ‘‘no nausea’’ and a higher score represents
‘‘more severe delayed nausea.’’ Patients were asked to indi-
cate the number on the Nausea Visual Analog Scale once
daily during a 4-day period after chemotherapy. The frequency
of delayed vomiting was defined by asking patients to fill in
a daily diary record of vomiting frequency. The vomiting epi-
sode was defined as single vomiting, and the next vomiting
episode was defined as 1 minute after the previous vomiting
episode.16 The delayed emesis was dichotomized into ‘‘re-
sponse’’ and ‘‘no response’’ based on the patient’s daily diary
record. Patients were grouped into ‘‘response’’ if they did not
experience nausea on 0 to 25 scores and did not vomit during
4 days after chemotherapy. Patients were grouped into ‘‘no
response’’ if they experienced nausea and vomiting during the
4 days after chemotherapy.16
Statistical Analysis
Raw QoL scores were transformed into function scales,
which range from 0 to 100. On the EORTC QLQ-C30, higher
scales scores on the dimensions indicate better function, that
is, better QoL. Higher scores in symptoms indicate more se-
vere symptoms, that is, lower QoL. Symptoms scores are as-
sessed with the EORTC QLQ-C30, whereas dimension scores
of the functioning are measured with both EORTC QLQ-C30
and SF-36. Higher scores on the SF-36 indicate better QoL,
except for fatigue and bodily pain where higher scores indicate
more severe symptoms.
Descriptive data are presented as means and SDs. Dif-
ferences of patients’ QoL before and after chemotherapeutic
treatment were analyzed using Student t test. Differences in
functions and scales between the 2 groups of delayed emesis
were defined by an independent t test. P G 0.05 was consid-
ered statistically significant.
RESULTS
Patients’ characteristics are summarized in Table 1. Of
the 186 female cancer patients, 64.5% had cervical cancer,
27.4% had ovarian cancer, 4.3% had uterine cancer, and 3.8%
patients were diagnosed with vulva cancer. The mean (SD)
age of patients was 48.3 (19.8) years. Most of the patients had
graduated from high school (34.4%), whereas 32.3% of pa-
tients did not have formal education. Comorbidity was present
in 15.6% of patients with 1 disease and 0.5% of patients with
2 diseases.
The available cytostatic drugs for the patients in this
hospital were cisplatin, cyclophosphamide, doxorubicin, and
5-fluorouracil. In the cervical cancer group, most of the pa-
tients who had limited pelvic cervical cancer (73.3%) were
treated with cisplatin as a single agent or in combination
with 5-fluorouracil, although this is not a standard schedule.
The dose of cisplatin as a single agent was 70 mg/m2 every
3 weeks, whereas the dose of cisplatin was 50 mg/m2 in com-
bination with 500 mg/m2 of 5-fluorouracil every week. In the
ovarian cancer group with limited stage (62.0%), the treatment
consisted of 500 mg/m2 of cyclophosphamide, 50 mg/m2 of
adriamycin, and 50 mg/m2 of cisplatin every 3 weeks.
The baseline QoL scores of all subjects are listed in
Table 2. We compared the baseline QoL in these data with the
reference studies.12,15 For this comparison, we have relied on
TABLE 1. Patients’ characteristics
Age (n = 181), mean (SD), y 48.3 (19.8)
Education (n = 181), n (%)
No education 60 (32.3)
Elementary school 50 (26.9)
High school 64 (34.4)
Bachelor/diploma 12 (6.5)
Type of gynecologic cancer (n = 186), n (%)
Cervical cancer 120 (64.5)
Ovarian cancer 51 (27.4)
Uterine cancer 8 (4.3)
Vulva cancer 7 (3.8)
Comorbidity (n = 186), n (%)
None 156 (83.9)
1 disease 29 (15.6)
2 diseases 1 (0.5)
Stage of cervical cancer (n = 120), n (%)
Limited to pelvic 88 (73.3)
Advanced stage 32 (26.7)
Stage of ovarian cancer (n = 50*), n (%)
Limited to pelvic 31 (62.0)
Advanced stage 19 (38.0)
Stage of uterine cancer (n = 13*), n (%)
Limited to pelvic 2 (25.0)
Advanced stage 3 (37.0)
Stage of vulva cancer, n (%)
Limited to pelvic 1 (14.3)
Advanced stage 6 (85.7)
*Missing data led to some minor differences in some of the
categories.
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a publication12 for which the raw data were not available for
us. As a result, it was not possible to adjust this comparison
for confounding factors with a multivariate analysis. In the
EORTC QLQ-C30, the functions score of this present study in
both of the questionnaires were lower than those in reference
studies, except for emotional function and cognitive function.
Meanwhile, the symptoms scores such as pain, fatigue, nausea
and vomiting, sleeping difficulty, appetite loss, and constipa-
tion were higher than those of reference studies. The signifi-
cant differences of function scores were shown by all functions
and symptoms, except for emotional function, nausea and
vomiting, and diarrhea (P G 0.001). Moreover, the Indonesian
cancer patients faced higher financial difficulty than the Dutch
population. In the SF-36, the Indonesian cancer patients
showed significantly lower functions and symptoms than those
of the reference study (P G 0.05).
Seven patients died in this study during the delayed
phase due to their cancer. Most patients (74.9%) experienced
delayed emesis in the 4 days after chemotherapy, that is, a
response to the attempt to prevent nausea and vomiting. The
patients’ functions in the baseline and after chemotherapy
based on the patients’ response are presented in Figure 1.
At baseline, no significant differences between the response
group and the no-response group were found for any of the
QoL domains and symptoms scale.
On the EORTC QLQ-C30, the patients’ functions did
not change much or even deteriorated after the chemother-
apy. Fatigue was experienced by both response group and
no-response group patients (Fig. 1). Meanwhile, in the SF-36,
general health perceptions, emotional function, and social
function were improved after chemotherapy. Figure 2 shows
the patients’ symptoms at baseline and after chemotherapy
based on the response and the no-response groups. This fig-
ure shows that the nonresponse patients experienced more
severe dyspnea, sleeping difficulty, appetite loss, and consti-
pation after chemotherapy than at baseline.
The impact of delayed emesis on QoL dimensions in
patients with and those without a response is presented in
Table 3. Significant differences between the 2 groups in symp-
toms, such as fatigue, nausea, vomiting, and appetite loss, were
found on the EORTCQLQ-C30 questionnaire. The no-response
patients experienced more severe symptoms than response
TABLE 2. Comparison of baseline patients’ QoL in this study and the reference studies
Baseline of This Study Baseline of the Reference Data12,15 P
EORTC QLQ-C30 n = 186 n = 796
General QoL 60 (15) 77 (18) G0.001
Physical function 77 (20) 89 (17) G0.001
Role function 68 (25) 87 (22) G0.001
Emotional function 94 (12) 88 (17) 0.004
Cognitive function 95 (10) 92 (16) G0.001
Social function 72 (23) 93 (18) G0.001
Pain 33 (25) 18 (24) G0.001
Fatigue 25 (21) 20 (21) G0.005
Nausea vomiting 5 (13) 3.9 (13) 0.300
Dyspnea 5 (14) 7.6 (18) G0.001
Sleeping difficulty 32 (30) 17 (26) G0.001
Appetite loss 18 (25) 4.4 (14) G0.001
Constipation 13 (24) 6.5 (17) G0.001
Diarrhea 4 (26) 3.8 (14) 0.942
Financial difficulty 48 (48) 3.6 (13) G0.001
SF-36 n = 186 n = 180
General health perceptions 52.9 (15.2) 71.6 (23.0) G0.001
Physical function 51.1 (30.6) 79.9 (24.7) G0.001
Physical role functioning 30.0 (40.9) 78.9 (37.0) G0.001
Emotional role functioning 32.8 (43.5) 83.6 (33.1) G0.001
Mental health 63.2 (22.8) 76.7 (19.6) G0.001
Social function 54.1 (22.0) 86.1 (21.8) G0.001
Bodily pain 58.2 (27.5) 80.5 (26.7) G0.001
Fatigue 61.2 (18.9) 67.5 (20.3) 0.002
Health change 42.8 (28.7) 51.9 (19.8) G0.001
Values are means (SD); bold P values show the significant differences of baseline Qol scores between this study and the reference studies.
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patients in whom the attempted prevention of nausea and
vomiting was effective, according to the diary data. Significant
differences between the 2 groups on QoL dimensions, such as
physical function, mental function, social function, and bodily
pain, were also found using the SF-36 questionnaire. The di-
mensions score show that the no-response patients had lower
QoL than the response patients. This study also found that
both the response group and the no-response group showed
the score deterioration in most of the dimensions and experi-
enced worse symptoms compared with the baseline score
(Table 3). Other factors that could have a negative impact on
patients’ QoL are the patients’ characteristics such as comor-
bidity, cancer diagnosis, and stage of cancer. Meanwhile, only
comorbidity showed significant impact on the physical func-
tion, pain, and fatigue symptoms (data are not presented).
DISCUSSION
Our results show that, despite optimal initial prophy-
lactic use of antiemetics followed by suboptimal prophylaxis
for delayed nausea and emesis, most patients with gyneco-
logic cancer experience delayed emesis. We have to take into
account that the standard of prophylactic antiemetic drugs
FIGURE 1. Scores on the EORTC QLQ-C30 and SF-36
at baseline and after chemotherapy in the response
and no-response groups. CF indicates cognitive
function; EF, emotional function; EP, emotional problem;
Fa, fatigue; GH, general health; GQL, general QoL; Pa,
pain; PF, physical function; PR, physical role; RF, role
function; SF, social function.
FIGURE 2. Symptoms on the EORTC QLQ-C30 at
baseline and after chemotherapy for the response and
no-response groups.
TABLE 3. Quality of life functions 5 days after
chemotherapy based on delayed emesis
Response
Group
(n = 45)
No-Response
Group
(n = 134) P
EORTC QLQ-C30
General QoL 58.4 (17.5) 58.4 (16.4) 0.979
Physical function 71.6 (24.3) 70.0 (22.1) 0.673
Role function 66.6 (24.2) 64.5 (24.8) 0.590
Emotional function 93.9 (15.3) 93.7 (13.2) 0.956
Cognitive function 93.3 (16.3) 92.7 (14.7) 0.799
Social function 70.3 (19.9) 72.1 (22.7) 0.592
Pain 26.1 (24.6) 31.9 (25.1) 0.142
Fatigue 34.1 (22.2) 41.3 (20.9) 0.032
Nausea vomiting 21.7 (25.8) 47.3 (25.2) G 0.001
Dyspnea 5.0 (16.0) 6.2 (16.2) 0.650
Sleeping difficulty 27.2 (29.1) 33.9 (28.2) 0.140
Appetite loss 30.0 (31.1) 48.2 (28.0) G 0.001
Constipation 11.7 (24.4) 18.5 (38.9) 0.218
Diarrhea 5.0 (17.2) 5.0 (34.6) 0.993
Financial difficulty 35.6 (25.2) 38.9 (27.2) 0.423
SF-36
General health
perceptions
62.4 (20.5) 59.1 (19.3) 0.121
Physical function 57.6 (31.4) 46.1 (32.4) 0.025
Physical role
function
23.8 (39.4) 27.9 (39.6) 0.504
Emotional role
function
31.7 (45.3) 25.5 (41.3) 0.362
Mental health 77.4 (33.1) 65.9 (30.9) 0.024
Social function 63.3 (24.6) 53.2 (21.3) 0.005
Bodily pain 69.8 (27.4) 60.8 (25.9) 0.034
Fatigue 64.6 (19.1) 61.3 (17.4) 0.241
Health change 57.9 (33.1) 51.1 (24.9) 0.287
Values are means (SD).
Significant score differences between the response and no-
response groups are indicated in bold.
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that are used at our hospital is suboptimal. Despite this short-
coming, we decided to study the relationship of CINVand QoL.
A previous study showed that around 70% of patients
receiving chemotherapy in a community hospital experienced
delayed emesis.17 The present study shows a similar percent-
age of subjects experiencing delayed emesis (ie, 74.9%). All
patients were treated by a standard antiemetic regimen con-
sisting of ondansetron and dexamethasone 1 hour before the
cisplatin treatment. Because of the cost of further ondanse-
tron with dexamethasone and certainly aprepitant, suboptimal
therapy with oral metoclopramide was prescribed for delayed
emesis/vomiting. On the basis of the international guidelines,
ondansetron or granisetron in combination with dexametha-
sone on days 2 to 5 should be given after a highly emetogenic
chemotherapy to prevent delayed emesis.7 All of our patients
were treated with metoclopramide for 5 days, after cisplatin
treatment. Only 34.3% patients had complete response in the
delayed phase. Poor control of patients’ symptoms after che-
motherapy interfered our study patients’ QoL. In another study,
the efficacy of metoclopramide was increased significantly by
the augmentation of dexamethasone.18
The delayed emesis in our patient sample led to a sig-
nificant negative impact on the patients’ QoL. Significant
impact was illustrated by more severe symptoms, such as
fatigue, nausea, vomiting, appetite loss, and pain after che-
motherapy. Interestingly, the patients who did not experi-
ence delayed emesis also showed a deterioration of QoL. The
scores of the various QoL dimensions in EORTC QLQ-C30
questionnaire were lower than those in reference groups before
the chemotherapy treatment. The symptom scores were also
higher than those in the reference groups. This probably indi-
cates that Indonesian gynecologic cancer patients have lower
QoL and experience more severe symptoms than the same
groups in the Netherlands before start of chemotherapy, pos-
sibly related to the suboptimal treatment of delayed nausea/
emesis. A recent study in France suggested that the deteriora-
tion of physical function, role function, and general health
could be a reason for impaired QoL in newly diagnosed cancer
patients.19
The present study showed that delayed emesis affects
patients’ symptoms such as fatigue, appetite loss, and bodily
pain. The higher score of the functions in the response group
and the significant differences of function scores between
the patients of the response group and the no-response group
indicate that delayed emesis interferes with patients’ daily
function. Both response and no-response groups showed that
CINV interferes with patients’ QoL. These findings are sim-
ilar to other studies of cancer patients treated with moderately
to highly emetogenic chemotherapy, despite the use of anti-
emetic drugs. In addition, acute CINV affects patients’ QoL
even for patients who do not experience nausea or vomiting
during the delayed phase.20 The patients’ comorbidity should
be considered as well as a factor that can affect physical func-
tion, pain, and fatigue.
In general, patients’ QoL was decreased in our study
after chemotherapy compared with baseline. These findings
are similar to another study in a community oncology set-
ting across the United States, which revealed that CINV sig-
nificantly interferes with patients’ QoL.1 Our study included
cancer patients who received their first chemotherapy course
with various emetogenic chemotherapy schedules.
General health perception, emotional, and social func-
tions were maintained. This could be explained by the role of
family and neighborhood support. One characteristic of the
Indonesian society, especially in the rural area, is that many
people come to the patient’s house to give psychological sup-
port when the patient comes back from the hospital. This
finding is supported by Noonan20 who reported that patients’
QoL was not only affected by the symptoms of cancer and
the adverse effect of treatment but also by the psychosocial
condition, such as family support. The study of survivorship
in cancer patients suggested that the ability to return to
family, social, and work activities was an essential part of
survivorship.21
Another study that used the Functional Living Index of
Emesis (FLIE) as the QoL instrument to study the relation-
ship between CINVand patients’ QoL revealed that the score
of FLIE after chemotherapy decreased significantly, in the
range of 21.6% to 24.4%. Patients with CINV also had a de-
crease of health utility in the range of 15% to 6.9%.22 In
addition, it has been reported that both acute and delayed
emesis have a significant impact on patients’ daily function-
ing. Furthermore, it is frequently underreported and untreated
because the patients experience these symptoms after they
have left the hospital.1 In our hospital, a similar situation exists
because patients leave the hospitals, on average, 4 hours after
the chemotherapy has been given.
Different health care providers in the Western world
have variously predicted the incidence rates of CINV, and
their prediction in prescription of antiemetics has also varied.
For example, in patients receiving highly emetogenic chemo-
therapy, the use of 5-hydroxytryptamine receptor antagonists
and dexamethasone as antiemetics led to an underestima-
tion by the health providers in predicting delayed emesis.23
In contrast, the use of aprepitant in combination with dexa-
methasone and 5-hydroxytryptamine receptor antagonists led
to health care providers’ overestimation in predicting de-
layed CINV. Furthermore, it has been suggested that the
health care providers increase their appreciation of delayed
CINV incidence by using structured patient-reported outcome
instruments.5
On the basis of the results in the present study, we also
recommend that the health care providers in Indonesia should
closely monitor delayed emesis and prescribe an appropriate
antiemetic prophylaxis.
The results of our study indicate that poor control of
delayed emesis in cancer patients treated by highly emeto-
genic chemotherapy unnecessarily reduces the patients’ QoL.
Thus, appropriately potent antiemetics should be used to
prevent delayed emesis. In clinical practice, the oncologist
who prescribes chemotherapy in combination with subop-
timal antiemetic prophylactic should be aware of delayed
CINV because the delayed emesis adversely affects patients
after they have left the hospital. Furthermore, the delayed
emesis should be closely monitored to improve the patients’
QoL and patients’ adherence in following the next cycles of
chemotherapy. Cognitive-behavioral interventions, counsel-
ing, and supportive therapy seem to be additional promising
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strategies to improve gynecologic cancer patients’ QoL and
their survivorship.1,21
CONCLUSIONS
Patients with gynecologic cancer in our study experi-
enced severe symptoms, such as fatigue, nausea, vomiting,
appetite loss, and pain after chemotherapy, despite adequate
prophylactic use of antiemetics for acute nausea and vomit-
ing but with insufficient prophylactic antiemetic therapy for
chronic nausea and vomiting. These symptoms affected other
domains as shown in both the EORTC QLQ-C30 and the
SF-36 questionnaires.
Poor control of patients’ chronic nausea and vomiting
after chemotherapy has a negative impact on patients’ QoL.
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